Comparison of NRAS‐mutation(+) and KRAS‐mutation(+) groups, indicated a significantly better prognosis for NRAS‐mutation(+) CRC (P = 3 × 10−4, log‐rank test). This evidence concerns the gene KRAS and colorectal carcinoma.